Author: Powell, M.; Clark, C.; Alyakin, A.; Vogelstein, J.; Hart, B. B.
Title: Metformin: We need to either put it in our drinking water or rethink how we study it Cord-id: o4txvd3d Document date: 2021_9_21
ID: o4txvd3d
Snippet: Objectives - To expose the potential impact of residual confounding in common observational study designs investigating metformin using a type 2 diabetes cohort; to propose a more robust study design for future observational studies of metformin. Design - Retrospective cohort studies using a prevalent user design conducted in two distinct cohorts: individuals with type 2 diabetes and individuals with prediabetes. Setting - Insurance claims database for Medicare Advantage beneficiaries in the Uni
Document: Objectives - To expose the potential impact of residual confounding in common observational study designs investigating metformin using a type 2 diabetes cohort; to propose a more robust study design for future observational studies of metformin. Design - Retrospective cohort studies using a prevalent user design conducted in two distinct cohorts: individuals with type 2 diabetes and individuals with prediabetes. Setting - Insurance claims database for Medicare Advantage beneficiaries in the United States, 2018-2019. An identical analysis of commercial insurance beneficiaries appears in the supplement. Participants - 404,765 individuals with type 2 diabetes, 81,791 individuals with prediabetes. Main outcome measures - Total inpatient admission days in 2019, total medical spend (excluding prescription drugs) in 2019. Each of these measures is treated as a binary outcome: greater than zero inpatient days and top 10% medical spend. Results - We implement a common observational study design and observe a strong metformin effect estimate associated with reduced inpatient admissions and reduced medical expenditures; we also implement a more robust study design that suggests any estimated effect is attributable to residual confounding related to individuals' overall health. Conclusions - Common observational study designs examining metformin in a type 2 diabetes population are likely impacted by significant residual confounding. By additionally considering numerous negative control outcomes and a complementary prediabetes cohort, the study design proposed here demonstrates efficacy at exposing residual confounding related to overall health, nullifying the claim derived from a standard study design. Trial registration - Preregistration available at https://osf.io/qf49p.
Search related documents:
Co phrase search for related documents- absence presence and adjusted effect: 1
- absence presence and adjusted odd ratio: 1
- absence presence and admission day: 1, 2
- absence presence and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63
- absence presence and logistic regression model: 1, 2, 3, 4, 5, 6, 7
- absence presence and low prevalence: 1, 2, 3, 4
- absolute risk and admission day: 1, 2, 3
- absolute risk and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- absolute risk and logistic regression model: 1, 2, 3, 4, 5
- absolute risk and low prevalence: 1
- absolute risk and macular degeneration: 1
Co phrase search for related documents, hyperlinks ordered by date